Rep. Jennifer Sanalitro opposes HB5492 mandating insurance for 12-month hormone therapy

During the 104th General Assembly on May 31, 2026, Rep. Jennifer Sanalitro (R-48th) voted against HB5492, legislation that requires insurance coverage for 12-month hormone therapy prescriptions. The Illinois House passed the bill with a vote of 75-39.

The official legislation refers to the provision as: "PRESCRIPTION HORMONE THERAPY."

The summary below draws directly from the language of the bill, with interpretive language included for clarity regarding its terms.

Beginning Jan. 1, 2028, the bill requires most individual and group health insurance policies in Illinois, including coverage for state employees and Medicaid recipients, to provide for up to a 12-month supply of prescription hormone therapy and related self-administration supplies when prescribed in-network and filled at one time. Covered prescriptions are specified, with glucagon-like peptide-1 drugs excluded. The bill authorizes insurers to employ drug management techniques and limit refills following a 12-month supply, and requires coordination for out-of-network coverage as needed. Pharmacists and providers, with some exceptions, must fill requests for up to a 12-month supply when asked by a patient.

HB5492’s most recent action recorded was 'Senate Floor Amendment No. 2 House Concurs.'

Sanalitro, a Republican elected in 2023, represents Illinois' 48th House District, succeeding Terra Costa Howard in the position.

Legislation in Illinois undergoes a multi-stage process which starts with the proposal's introduction in one chamber, followed by committee hearings and debate, before proceeding to floor votes in both chambers and finally consideration by the governor. The General Assembly conducts its operations on a two-year cycle, and although many bills are introduced, only a portion advance to become law.